Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC

ConditionAnaplastic Throid Carcinoma

Trial statusNot yet recruiting

Trial phasePhase 1, Phase 2

Trial typeInterventional

Biological sexAll

Age18-75

SponsorZhejiang Provincial People's Hospital

About this trial

The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18-75 years (including boundary values), male or female.

Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm.

Liver and kidney function is good, and can tolerate treatment.

Be able to cooperate with the completion of treatment and follow-up work.

Disqualifiers

Need to breastfeed the baby or have fertility needs；

Immune system diseases;

Diseases of the blood system;

Mental system diseases;

Trial design

Design model

Single group

Treatments tested in this trial

NKG2D CAR-NK with PD-1 Antibody
Drug
Treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.

Treatment groups

30 Participants

are divided into 1 treatment group

Group A: treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

Safety and tolerability

Safety and tolerability at 28 days after combination therapy, dose limiting toxicity (DLT) and maximum tolerated dose (MTD) were determined.

Time frame

From the start of the trial to day 56 after the first infusion of CAR-NK.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Zhejiang Provincial People's Hospital

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: